PMID- 26600713
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20151125
LR  - 20200930
IS  - 0973-1296 (Print)
IS  - 0976-4062 (Electronic)
IS  - 0973-1296 (Linking)
VI  - 11
IP  - 44
DP  - 2015 Oct-Dec
TI  - Metabolic differentiation and classification of abnormal Savda Munziq's 
      pharmacodynamic role on rat models with different diseases by nuclear magnetic 
      resonance-based metabonomics.
PG  - 698-706
LID - 10.4103/0973-1296.165551 [doi]
AB  - BACKGROUND: Abnormal Savda Munziq (ASMq) is a traditional Uyghur herbal 
      preparation used as a therapy for abnormal Savda-related diseases. In this study, 
      we investigate ASMq's dynamic effects on abnormal Savda rat models under 
      different disease conditions. MATERIALS AND METHODS: Abnormal Savda rat models 
      with hepatocellular carcinoma (HCC), type 2 diabetes mellitus (T2DM), and asthma 
      dosed of ASMq. Serum samples of each animal tested by nuclear magnetic resonance 
      spectroscopy and analyzed by orthogonal projection to latent structure with 
      discriminant analysis. RESULTS: Compared with healthy controls, HCC rats had 
      higher concentrations of amino acids, fat-related metabolites, lactate, 
      myoinositol, and citrate, but lower concentrations of alpha-glucose, beta-glucose, and 
      glutamine. Following ASMq treatment, the serum acetone very low-density 
      lipoprotein (VLDL), LDL, unsaturated lipids, acetylcysteine, and pyruvate 
      concentration decreased, but alpha-glucose, beta-glucose, and glutamine concentration 
      increased (P < 0.05). T2DM rats had higher concentrations of alpha- and beta-glucose, 
      but lower concentrations of isoleucine, leucine, valine, glutamine, glycoprotein, 
      lactate, tyrosine, creatine, alanine, carnitine, and phenylalanine. After ASMq 
      treated T2DM groups showed reduced alpha- and beta-glucose and increased creatine levels 
      (P < 0.05). Asthma rats had higher acetate, carnitine, formate, and phenylalanine 
      levels, but lower concentrations of glutamine, glycoprotein, lactate, VLDL, LDL, 
      and unsaturated lipids. ASMq treatment showed increased glutamine and reduced 
      carnitine, glycoprotein, formate, and phenylalanine levels (P < 0.05). 
      CONCLUSION: Low immune function, decreased oxidative defense, liver function 
      abnormalities, amino acid deficiencies, and energy metabolism disorders are 
      common characteristics of abnormal Savda-related diseases. ASMq may improve the 
      abnormal metabolism and immune function of rat models with different diseases 
      combined abnormal Savda.
FAU - Mamtimin, Batur
AU  - Mamtimin B
AD  - Central Laboratory, Xinjiang Medical University, Urumqi 830011, China.
FAU - Xia, Guo
AU  - Xia G
AD  - Central Laboratory, Xinjiang Medical University, Urumqi 830011, China.
FAU - Mijit, Mahmut
AU  - Mijit M
AD  - College of Basic Medicine, Xinjiang Medical University, Urumqi 830011, China.
FAU - Hizbulla, Mawlanjan
AU  - Hizbulla M
AD  - College of Traditional Uyghur Medicine, Xinjiang Medical University, Urumqi 
      830011, China.
FAU - Kurbantay, Nazuk
AU  - Kurbantay N
AD  - Central Laboratory, Xinjiang Medical University, Urumqi 830011, China.
FAU - You, Li
AU  - You L
AD  - College of Traditional Uyghur Medicine, Xinjiang Medical University, Urumqi 
      830011, China.
FAU - Upur, Halmurat
AU  - Upur H
AD  - College of Traditional Uyghur Medicine, Xinjiang Medical University, Urumqi 
      830011, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Pharmacogn Mag
JT  - Pharmacognosy magazine
JID - 101300403
PMC - PMC4621637
OTO - NOTNLM
OT  - Abnormal Savda
OT  - abnormal Savda Munziq
OT  - metabonomics
OT  - rat model
OT  - traditional Uyghur medicine
COIS- Conflict of Interest: None declared.
EDAT- 2015/11/26 06:00
MHDA- 2015/11/26 06:01
PMCR- 2015/10/01
CRDT- 2015/11/25 06:00
PHST- 2015/11/25 06:00 [entrez]
PHST- 2015/11/26 06:00 [pubmed]
PHST- 2015/11/26 06:01 [medline]
PHST- 2015/10/01 00:00 [pmc-release]
AID - PM-11-698 [pii]
AID - 10.4103/0973-1296.165551 [doi]
PST - ppublish
SO  - Pharmacogn Mag. 2015 Oct-Dec;11(44):698-706. doi: 10.4103/0973-1296.165551.